JNJ
RBC says J&J still has room to run
Johnson & Johnson got a little more love from RBC Capital, which lifted its price target to $265 from $255 and kept the stock at Outperform. Translation: the bank thinks J&J isn’t done flexing yet.
Why the analysts are smiling
RBC pointed to J&J’s first-quarter numbers, which came in ahead of expectations by about 2% on sales and 1% on earnings per share. That’s not a moonshot, but in big-cap pharma-land, steady beats are basically catnip.
The company’s reported Q1 2026 results backed that up:
- adjusted EPS came in at $2.70 vs. $2.68 expected
- revenue hit $24.1 billion vs. $23.61 billion forecast
What this means for your portfolio
The stock was already trading near its 52-week high, so this isn’t exactly a bargain-bin story. But when a giant like J&J keeps beating and the analysts keep lifting targets, it can help support the idea that the market’s still underestimating the business.
The one weird little twist? The shares dipped slightly in premarket trading anyway. Because of course they did—Wall Street loves a good earnings beat almost as much as it loves a pointless mood swing.
Big picture: for J&J, this is less about fireworks and more about proving the machine still works. And right now, the machine looks pretty well-oiled.